References - Neonatal Intensive Care Drug Manual

|
Neonatal Intensive Care Drug Manual
|
bet | 82/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
References
|
Altunaiji SM, Kukuruzovic RH, Curtis NC, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev [serial on the Internet]. 2007.
Centers for Disease Control and Prevention. Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis, 2005. MMWR Recomm Rep. 2005 December 9, 2005 / 54(RR14);1-16.
Hammerschlag MR, Gelling M, Roblin PM, Kutlin A, Jule JE. Treatment of neonatal chlamydial conjunctivitis with azithromycin. Pediatr Infect Dis J. 1998;17:1049-50.
Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342:453-6.
Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, House JI, Yu SN, Ray KJ, Emerson PM, Keenan JD, Porco TC, Lietman TM, Gaynor BD. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet. 2012;379:143-51.
Harding-Esch EM, Sillah A, Edwards T, Burr SE, Hart JD, Joof H, Laye M, Makalo P, Manjang A, Molina S, Sarr-Sissoho I, Quinn TC, Lietman T, Holland MJ, Mabey D, West SK, Bailey R, Partnership for Rapid Elimination of Trachoma study g. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. [Erratum appears in PLoS Negl Trop Dis. 2013 Jun;7(6). doi:10.1371/annotation/0bae8b34-5ae7-4044-a071-8d88d520a01b]. PLoS Negl Trop Dis. 2013;7:e2115.
American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.
Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1:CD004875.
Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL, Mace SE, McCracken Jr GH, Moore MR, St Peter SD. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical infectious diseases. 2011;53(7):e25-76.
Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia: a systematic review and meta-analysis. Neonatology. 2014;106(4):337-47.
Merchan LM, Hassan HE, Terrin ML, Waites KB, Kaufman DA, Ambalavanan N, Donohue P, Dulkerian SJ, Schelonka R, Magder LS, Shukla S. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. Antimicrobial agents and chemotherapy. 2015;59(1):570-8.
Micromedex. Accessed on 29 May 2018.
Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics. 2015;135(3):483-8.
Smith C, Egunsola O, Choonara I, Kotecha S, Jacqz-Aigrain E, Sammons H. Use and safety of azithromycin in neonates: a systematic review. BMJ Open. 2015;5:e008194.
Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Viscardi RM. Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia. The Journal of Clinical Pharmacology 2011;51(9):1264-75.
Australian injectable Drugs Handbook online 18 April 2018.
Tajima T, Kobayashi M, Abe T, Fujii R. Pharmacokinetic, bacteriological and clinical studies on azithromycin in children. The Japanese journal of antibiotics. 1997 Feb;50(2):200-5.
|
Original version Date: 20/06/2018
|
Author: NeoMed Consensus Group
|
Current Version number: 2
|
Current Version Date: 2/3/2021
|
Risk Rating: Medium
|
Due for Review: 2/3/2024
|
Approved by: DTC
|
Approval Date: TBA
|
|
| |